cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2020.4.n1063cardio-1063Research ArticleОБЗОРЫREVIEWSВзгляд на гипертрофию миокарда с позиции транскриптомики и метаболомикиFocus on the Myocardial Hypertrophy from the Perspective of Transcriptomics and Metabolomicshttps://orcid.org/0000-0001-5473-9394ШакарьянцГ. А.ShakaryantsG. A.

к.м.н., ассистент кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, PhD, Assistant, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruhttps://orcid.org/0000-0003-4778-7755КожевниковаМ. В.KozhevnikovaM. V.

к.м.н., асс. кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, PhD, Assistant, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruКаплуноваВ. Ю.KaplunovaV. Yu.

д.м.н., доцент кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, PhD, Associate Professor, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruhttps://orcid.org/0000-0002-9908-9476ПриваловаЕ. В.PrivalovaE. V.

д.м.н., проф. кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, PhD, Professor, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruЛишутаА. С.LishutaA. S.

к.м.н., доцент кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, PhD, Associate Professor, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruhttps://orcid.org/0000-0003-2873-704XКоробковаЕ. О.KorobkovaE. O.

аспирант кафедры Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

MD, postgraduate student, Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruhttps://orcid.org/0000-0002-3014-6129БеленковЮ. Н.BelenkovYu. N.

академик РАН, д.м.н., проф., зав. кафедрой Госпитальной терапии №1 ИКМ им. Н.В. Склифосовского Сеченовского Университета

Academician of the Russian Academy of Sciences, MD, PhD, Professor, Head of Chair of Hospital Therapy №1, Sechenov University

shakaryants@bk.ruФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет) Министерства здравоохранения Российской Федерации,РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202030032020604120129Copyright © Kardiomag, 20202020KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/1063

В обзоре представлены основные направления в изучении гипертрофии миокарда с позиции транскриптомики и метаболомики. Понимание механизмов, запускающих гипертрофию миокарда, позволит перейти от фундаментальных исследований к персонифицированному клиническому применению инновационных технологий в лечении заболеваний сердца, таких как таргетная терапия. В настоящее время разработаны определенные методы диагностики и прогнозирования сердечно-сосудистых заболеваний, основанные на метаболомном профилировании и оценке экспрессии микроРНК. Прогресс в области изучения молекулярных и генетических процессов, лежащих в основе развития сердечно-сосудистых заболеваний, может дать неоценимо важную информацию для клинической кардиологии.

This review presents major directions in studies of myocardial hypertrophy from the aspect of transcriptomics and metabolomics. Understanding of trigger mechanisms of myocardial hypertrophy will permit transition from basic studies to individualized clinical application of innovative technologies in the treatment of heart diseases, such as targeted therapy. At the present time, methods have been developed for diagnostics and prediction of cardiovascular diseases based on the metabolomic profiling and the evaluation of microRNA expression. Progress in studying molecular and genetic processes underlying the development of cardiovascular diseases may provide invaluable information for clinical cardiology.

Гипертрофия миокардатранскриптомикаметаболомикамикроРНКметаболомное профилированиеMyocardial hypertrophytranscriptomicsmetabolomicsmicroRNAmetabolomic profilingРабота выполнена при финансовой поддержке РФФИ в рамках научного проекта «Разработка персонифицированной методики ранней диагностики и прогнозирования варианта течения гипертрофической кардиомиопатии на основании анализа микроРНК-21, -133а, определяющих степень гипертрофии и фиброза миокарда» (№18-015-00415 А). Поддерживается «Проектом повышения конкурентоспособности ведущих российских университетов среди ведущих мировых научно-образовательных центров».ReferencesThakur C, Chen F. Connections between metabolism and epigenetics in cancers. Seminars in Cancer Biology. 2019;57:52–8. DOI: 10.1016/j.semcancer.2019.06.006Thakur C, Chen F. Connections between metabolism and epigenetics in cancers. Seminars in Cancer Biology. 2019;57:52–8. DOI: 10.1016/j.semcancer.2019.06.006Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews Molecular Cell Biology. 2007;8(1):23–36. DOI: 10.1038/nrm2085Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews Molecular Cell Biology. 2007;8(1):23–36. DOI: 10.1038/nrm2085Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research. 2008;19(1):92–105. DOI: 10.1101/gr.082701.108Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research. 2008;19(1):92–105. DOI: 10.1101/gr.082701.108He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics. 2004;5(7):522–31. DOI: 10.1038/nrg1379He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics. 2004;5(7):522–31. DOI: 10.1038/nrg1379Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73. DOI: 10.1038/nature03315Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73. DOI: 10.1038/nature03315Sayed ASM, Xia K, Salma U, Yang T, Peng J. Diagnosis, Prognosis and Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases. Heart, Lung and Circulation. 2014;23(6):503–10. DOI: 10.1016/j.hlc.2014.01.001Sayed ASM, Xia K, Salma U, Yang T, Peng J. Diagnosis, Prognosis and Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases. Heart, Lung and Circulation. 2014;23(6):503–10. DOI: 10.1016/j.hlc.2014.01.001Luo Z, Zhang L, Li Z, Li X, Li G, Yu H et al. An in silicoanalysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Medical Genomics. 2012;5(1):3. DOI: 10.1186/1755-8794-5-3Luo Z, Zhang L, Li Z, Li X, Li G, Yu H et al. An in silicoanalysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Medical Genomics. 2012;5(1):3. DOI: 10.1186/1755-8794-5-3Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. Journal of Cellular and Molecular Medicine. 2008;13(1):24–38. DOI: 10.1111/j.1582-4934.2008.00534.xSonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. Journal of Cellular and Molecular Medicine. 2008;13(1):24–38. DOI: 10.1111/j.1582-4934.2008.00534.xXu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver International. 2012;32(5):752–60. DOI: 10.1111/j.1478-3231.2011.02750.xXu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver International. 2012;32(5):752–60. DOI: 10.1111/j.1478-3231.2011.02750.xDumortier O, Obberghen E. MicroRNAs in pancreas development. Diabetes, Obesity and Metabolism. 2012;14(Suppl 3):22–8. DOI: 10.1111/j.1463-1326.2012.01656.xDumortier O, Obberghen E. MicroRNAs in pancreas development. Diabetes, Obesity and Metabolism. 2012;14(Suppl 3):22–8. DOI: 10.1111/j.1463-1326.2012.01656.xHinton A, Hunter S, Reyes G, Fogel GB, King CC. From Pluripotency to Islets. Advances in Genetics. 2012;79:1–34. DOI: 10.1016/B978-0-12-394395-8.00001-3Hinton A, Hunter S, Reyes G, Fogel GB, King CC. From Pluripotency to Islets. Advances in Genetics. 2012;79:1–34. DOI: 10.1016/B978-0-12-394395-8.00001-3Ouyang L, Shi Z, Zhao S, Wang F-T, Zhou T-T, Liu B et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Proliferation. 2012;45(6):487–98. DOI: 10.1111/j.1365-2184.2012.00845.xOuyang L, Shi Z, Zhao S, Wang F-T, Zhou T-T, Liu B et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Proliferation. 2012;45(6):487–98. DOI: 10.1111/j.1365-2184.2012.00845.xAmbros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. DOI: 10.1038/nature02871Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. DOI: 10.1038/nature02871Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research. 2008;18(10):997–1006. DOI: 10.1038/cr.2008.282Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research. 2008;18(10):997–1006. DOI: 10.1038/cr.2008.282Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436(7048):214–20. DOI: 10.1038/nature03817Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436(7048):214–20. DOI: 10.1038/nature03817Sayed D, Hong C, Chen I-Y, Lypowy J, Abdellatif M. MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy. Circulation Research. 2007;100(3):416–24. DOI: 10.1161/01.RES.0000257913.42552.23Sayed D, Hong C, Chen I-Y, Lypowy J, Abdellatif M. MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy. Circulation Research. 2007;100(3):416–24. DOI: 10.1161/01.RES.0000257913.42552.23van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science. 2007;316(5824):575–9. DOI: 10.1126/science.1139089van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science. 2007;316(5824):575–9. DOI: 10.1126/science.1139089van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences. 2006;103(48):18255–60. DOI: 10.1073/pnas.0608791103van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences. 2006;103(48):18255–60. DOI: 10.1073/pnas.0608791103Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Research. 2004;32(22):e188. DOI: 10.1093/nar/gnh186Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Research. 2004;32(22):e188. DOI: 10.1093/nar/gnh186Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of Tissue-Specific MicroRNAs from Mouse. Current Biology. 2002;12(9):735–9. DOI: 10.1016/S0960-9822(02)00809-6Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of Tissue-Specific MicroRNAs from Mouse. Current Biology. 2002;12(9):735–9. DOI: 10.1016/S0960-9822(02)00809-6Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a Biomarker of Myocardial Injury. Clinical Chemistry. 2009;55(11):1944–9. DOI: 10.1373/clinchem.2009.125310Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a Biomarker of Myocardial Injury. Clinical Chemistry. 2009;55(11):1944–9. DOI: 10.1373/clinchem.2009.125310O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences. 2007;104(5):1604–9. DOI: 10.1073/pnas.0610731104O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences. 2007;104(5):1604–9. DOI: 10.1073/pnas.0610731104Condorelli G, Latronico MVG, Dorn GW. MicroRNAs in heart disease: putative novel therapeutic targets? European Heart Journal. 2010;31(6):649–58. DOI: 10.1093/eurheartj/ehp573Condorelli G, Latronico MVG, Dorn GW. MicroRNAs in heart disease: putative novel therapeutic targets? European Heart Journal. 2010;31(6):649–58. DOI: 10.1093/eurheartj/ehp573Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urologic Oncology. 2010;28(6):655–61. DOI: 10.1016/j.urolonc.2009.01.027Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urologic Oncology. 2010;28(6):655–61. DOI: 10.1016/j.urolonc.2009.01.027Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research. 2010;38(20):7248–59. DOI: 10.1093/nar/gkq601Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research. 2010;38(20):7248–59. DOI: 10.1093/nar/gkq601Kang K, Peng X, Luo J, Gou D. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. Journal of Animal Science and Biotechnology. 2012;3(1):4–12. DOI: 10.1186/2049-1891-3-4Kang K, Peng X, Luo J, Gou D. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. Journal of Animal Science and Biotechnology. 2012;3(1):4–12. DOI: 10.1186/2049-1891-3-4Kochetov A.G., Zhirov I.V., Masenko V.P., Gimadiev R.R., Lyang O.V., Tereschenko S.N. Prospects for the use of miRNA in the diagnosis and treatment of heart failure. Kardiologicheskii Vestnik. 2014;9(2):62–7. [Russian: Кочетов А.Г., Жиров И.В., Масенко В.П., Гимадиев Р.Р., Лянг О.В., Терешенко С.Н. Перспективы применения микроРНК в диагностике и терапии сердечной недостаточности. Кардиологический Вестник. 2014;9(2):62-7]Kochetov A.G., Zhirov I.V., Masenko V.P., Gimadiev R.R., Lyang O.V., Tereschenko S.N. Prospects for the use of miRNA in the diagnosis and treatment of heart failure. Kardiologicheskii Vestnik. 2014;9(2):62–7. [Russian: Кочетов А.Г., Жиров И.В., Масенко В.П., Гимадиев Р.Р., Лянг О.В., Терешенко С.Н. Перспективы применения микроРНК в диагностике и терапии сердечной недостаточности. Кардиологический Вестник. 2014;9(2):62-7]Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Molecular Medicine. 2012;4(1):3–14. DOI: 10.1002/emmm.201100191Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Molecular Medicine. 2012;4(1):3–14. DOI: 10.1002/emmm.201100191Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P et al. Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients with Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2014;63(9):920–7. DOI: 10.1016/j.jacc.2013.09.041Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P et al. Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients with Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2014;63(9):920–7. DOI: 10.1016/j.jacc.2013.09.041Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography. Proceedings of the National Academy of Sciences. 1971;68(10):2374–6. DOI: 10.1073/pnas.68.10.2374Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography. Proceedings of the National Academy of Sciences. 1971;68(10):2374–6. DOI: 10.1073/pnas.68.10.2374Cheng S, Shah SH, Corwin EJ, Fiehn O, Fitzgerald RL, Gerszten RE et al. Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Genetics. 2017;10(2):e000032. DOI: 10.1161/HCG.0000000000000032Cheng S, Shah SH, Corwin EJ, Fiehn O, Fitzgerald RL, Gerszten RE et al. Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation: Cardiovascular Genetics. 2017;10(2):e000032. DOI: 10.1161/HCG.0000000000000032Perrino C, Barabási A-L, Condorelli G, Davidson SM, De Windt L, Dimmeler S et al. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research. 2017;113(7):725–36. DOI: 10.1093/cvr/cvx070Perrino C, Barabási A-L, Condorelli G, Davidson SM, De Windt L, Dimmeler S et al. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research. 2017;113(7):725–36. DOI: 10.1093/cvr/cvx070Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovascular Research. 2010;86(3):461–70. DOI: 10.1093/cvr/cvp414Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovascular Research. 2010;86(3):461–70. DOI: 10.1093/cvr/cvp414Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J et al. Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart: A Multisystems Approach. Circulation: Heart Failure. 2014;7(6):1022–31. DOI: 10.1161/CIRCHEARTFAILURE.114.001469Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J et al. Energy Metabolic Reprogramming in the Hypertrophied and Early Stage Failing Heart: A Multisystems Approach. Circulation: Heart Failure. 2014;7(6):1022–31. DOI: 10.1161/CIRCHEARTFAILURE.114.001469Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial Fatty Acid Metabolism in Health and Disease. Physiological Reviews. 2010;90(1):207–58. DOI: 10.1152/physrev.00015.2009Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial Fatty Acid Metabolism in Health and Disease. Physiological Reviews. 2010;90(1):207–58. DOI: 10.1152/physrev.00015.2009Drosatos K, Pollak NM, Pol CJ, Ntziachristos P, Willecke F, Valenti M-C et al. Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function. Circulation Research. 2016;118(2):241–53. DOI: 10.1161/CIRCRESAHA.115.306383Drosatos K, Pollak NM, Pol CJ, Ntziachristos P, Willecke F, Valenti M-C et al. Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function. Circulation Research. 2016;118(2):241–53. DOI: 10.1161/CIRCRESAHA.115.306383Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Current Opinion in Lipidology. 2011;22(2):86–92. DOI: 10.1097/MOL.0b013e3283428d9dFernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Current Opinion in Lipidology. 2011;22(2):86–92. DOI: 10.1097/MOL.0b013e3283428d9dEl-Aroussy W, Rizk A, Mayhoub G, Aleem SA, El-Tobgy S. Plasma carnitine levels as a marker of impaired left ventricular functions. Molecular and Cellular Biochemistry. 2000;213(1–2):37–41. DOI: 10.1023/A:1007142919941El-Aroussy W, Rizk A, Mayhoub G, Aleem SA, El-Tobgy S. Plasma carnitine levels as a marker of impaired left ventricular functions. Molecular and Cellular Biochemistry. 2000;213(1–2):37–41. DOI: 10.1023/A:1007142919941Evaristi MF, Caubère C, Harmancey R, Desmoulin F, Peacock WF, Berry M et al. Increased mean aliphatic lipid chain length in left ventricular hypertrophy secondary to arterial hypertension: A cross-sectional study. Medicine. 2016;95(46):e4965. DOI: 10.1097/MD.0000000000004965Evaristi MF, Caubère C, Harmancey R, Desmoulin F, Peacock WF, Berry M et al. Increased mean aliphatic lipid chain length in left ventricular hypertrophy secondary to arterial hypertension: A cross-sectional study. Medicine. 2016;95(46):e4965. DOI: 10.1097/MD.0000000000004965Fisher DJ. Oxygenation and metabolism in the developing heart. Seminars in Perinatology. 1984;8(3):217–25. PMID: 6234661Fisher DJ. Oxygenation and metabolism in the developing heart. Seminars in Perinatology. 1984;8(3):217–25. PMID: 6234661Kolwicz SC, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovascular Research. 2011;90(2):194–201. DOI: 10.1093/cvr/cvr071Kolwicz SC, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovascular Research. 2011;90(2):194–201. DOI: 10.1093/cvr/cvr071Goikoetxea M, Beaumont J, Gonzalez A, Lopez B, Querejeta R, Larman M et al. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovascular Research. 2006;69(4):899–907. DOI: 10.1016/j.cardiores.2005.11.016Goikoetxea M, Beaumont J, Gonzalez A, Lopez B, Querejeta R, Larman M et al. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovascular Research. 2006;69(4):899–907. DOI: 10.1016/j.cardiores.2005.11.016Neubauer S. The Failing Heart – An Engine Out of Fuel. New England Journal of Medicine. 2007;356(11):1140–51. DOI: 10.1056/NEJMra063052Neubauer S. The Failing Heart – An Engine Out of Fuel. New England Journal of Medicine. 2007;356(11):1140–51. DOI: 10.1056/NEJMra063052Lorén C, Dahl C, Do L, Almaas V, Geiran O, Mörner S et al. Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy. Cells. 2019;8(2):97. DOI: 10.3390/cells8020097Lorén C, Dahl C, Do L, Almaas V, Geiran O, Mörner S et al. Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy. Cells. 2019;8(2):97. DOI: 10.3390/cells8020097Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients with Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients with Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2012;1826(1):129–69. DOI: 10.1016/j.bbcan.2012.03.008Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2012;1826(1):129–69. DOI: 10.1016/j.bbcan.2012.03.008Marques FZ, Prestes PR, Byars SG, Ritchie SC, Würtz P, Patel SK et al. Experimental and Human Evidence for Lipocalin‐2 (Neutrophil Gelatinase‐Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association. 2017;6(6):e005971. DOI: 10.1161/JAHA.117.005971Marques FZ, Prestes PR, Byars SG, Ritchie SC, Würtz P, Patel SK et al. Experimental and Human Evidence for Lipocalin‐2 (Neutrophil Gelatinase‐Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association. 2017;6(6):e005971. DOI: 10.1161/JAHA.117.005971

The authors declare that there are no conflicts of interest present.